Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Here's Why You Should Add PacBio Stock to Your Portfolio Now
02:45pm, Wednesday, 03'rd Jun 2026
PACB's growth is supported by HiFi sequencing advances and product momentum, though funding pressures weigh on instrument demand.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
12:11pm, Monday, 01'st Jun 2026
PACB expands HiFi sequencing reach with commercial availability of SPRQ-Nx for Revio, lowering costs by about 30% and adding AI and epigenetics upgrades.
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
09:05am, Tuesday, 26'th May 2026
New Revio multi-use SMRT Cells reduce sequencing costs by 30% compared to previous SPRQ chemistry while DeepConsensus improvements and expanded methylation calling increase accuracy, yield, and epigen
PacBio to Participate in the Jefferies Global Healthcare Conference
04:05pm, Thursday, 21'st May 2026
MENLO PARK, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
12:16pm, Wednesday, 20'th May 2026
PacBio teams with Blank Bio after its $7.2M seed round, using HiFi long reads to build RNA AI models from patient tumor samples.
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
09:00am, Tuesday, 19'th May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology.
Multinational study shows how one comprehensive genomic workflow and secure data collaboration may help reduce fragmented testing for couples seeking answers Multinational study shows how one comprehe
Pacific Biosciences of California Q1 Earnings Call Highlights
04:07pm, Friday, 08'th May 2026
Pacific Biosciences of California NASDAQ: PACB reported first-quarter 2026 revenue of $37.2 million, roughly flat year over year, as record consumables revenue offset weaker-than-expected instrument p
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
11:41am, Friday, 08'th May 2026
PacBio beats Q1 earnings estimates as consumables growth and cost cuts offset flat revenue and a weaker gross margin.
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
03:31am, Friday, 08'th May 2026
Pacific Biosciences of California, Inc. (PACB) Q1 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
07:01pm, Thursday, 07'th May 2026
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago
PacBio Announces First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
MENLO PARK, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2026.
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
12:50pm, Tuesday, 05'th May 2026
PACB heads into Q1 earnings with strong consumables momentum, but muted academic demand and macro pressures cloud near-term visibility.
Critical Review: Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB)
01:12am, Monday, 27'th Apr 2026
Autonomix Medical (NASDAQ: AMIX - Get Free Report) and Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) are both small-cap medical companies, but which is the better investment? We w
